Olema Oncology (OLMA) Remains a Top SMidcap Idea at Jefferies Ahead of Key Breast Cancer Data
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $70.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA) citing the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
